Baird Medical Investment Holdings Ltd reported a significant revenue drop in 2025 driven by reduced direct customer sales in its premier microwave ablation medical devices business focused on thyroid diseases. Despite its leadership position in China’s MWA needle market, the company’s gross margin contracted and operating expenses surged due to intensified R&D on AI-integrated robotic systems and expanded marketing efforts. Regulatory uncertainties and centralized procurement trends add to near-term headwinds. Baird Medical’s path to growth hinges on stabilizing demand, successful pipeline approvals, and balancing innovation with cost discipline.